Q-omics provides the consensus-scored TMEM248 profile across patient tissues and cancer cell-line models. TMEM248 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, TMEM248 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, TMEM248 RNA expression shows 19,837 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, HNSC, and ACC as cancer lineages where TMEM248 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM248 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM248 survival associations across molecular data types. TMEM248 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM248 RNA expression–survival associations across cancer types. High TMEM248 expression shows unfavorable associations in CESC, LGG, PAAD and SCLC, but favorable associations in UCS and THYM. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for TMEM248 RNA expression.
This table summarizes TMEM248 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM248. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM248 shows higher tumor expression in HNSC, LIHC, KIRP, KIRC, STAD and COAD. The HNSC box plot shows higher TMEM248 RNA expression in tumor versus normal tissue (log2 FC = +0.819, t-test p < 0.001).
This table shows molecular features associated with TMEM248 in patient tissues and cancer cell lines. In patient samples, TMEM248 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM248 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
